More Affordable Chelation Therapy Cost
Heavy metal toxicity is now a worldwide epidemic, and there exists a growing need for more affordable chelation treatment methods, due to the chelation therapy cost and more affordable EDTA chelation method is needed.
Chelation therapy (from the Greek word chela, meaning "claw"), is the administration of a substance (IV, Detoxamin EDTA Suppositories are the lowest chelation therapy cost, Oral EDTA, along with natural "chelators", such as certain vitamins and other nutrients consumed orally, exert some of the same action) which has the ability to rid the body of heavy metals and minerals, substances usually thought of as toxic, and decidedly when they are in excess. The primary substance used is the synthetic amino acid Ethylene-diamine-tetraacetic acid (EDTA), known under other names and similar compounds.
EDTA, lower your chelation therapy cost
Understanding the way in which EDTA and similar compounds "bind to" toxic metals or minerals involves a knowledge of physics. The empirical reality is that such "binding" occurs, and the same result is that certain heavy, potentially toxic metals and minerals may be made soluble so they may be excreted through the kidneys, depending on the integrity of the same and other factors. Because some necessary minerals may also be removed in the process, a standard EDTA "drip" includes replacement minerals. But this is only needed if you do IV chelation, Detoxamin EDTA suppositories are 70% less the IV chelation therapy cost and uses oral vitamin and minerals for replacement.
While synthesized in Germany in 1931, it was an American - Dr Norman E. Clark Sr. MD, cardiologist at Providence Hospital, Detroit - who discovered the multiple uses of the compound ranging well beyond its utility in curing lead poisoning.
There is some conflicting information about the early days of the edta chelation therapy cost, including the scattered research on it which produces anything negative (and which is parroted today by the medical establishment), since scores of favorable appears were published at home and abroad (primarily during the 1950's) as to its effectiveness against several conditions, particularly arteriosclerosis. Indeed, as late as 1970 even the FDA referred to calcium EDTA or disodium EDTA this way:
This drug is possibly effective in occlusive vascular disorders and the treatment of pathologic conditions to which calcium tissue deposits of hypercalcemia may contribute...
As late as the early 1960's Abbot Laboratories' "package insert" for EDTA contained arteriosclerosis as an "indication" for its use. Back then had the lowest chelation therapy cost.
But it was also in the early 1960's that the Food, Drug, and Cosmetic Act was once again amended, with the FDA securing the power to oversee both the "safety" and "efficacy" of drugs - an event which vastly expanded FDA clout and also allowed the federal agency to be used as a weapon by gigantic companies to block competitors. It was also time for Abbot's patent on EDTA to run out increasing the chelation therapy cost to patients. To attempt to re-license an "old drug" for a new purpose meant in effect investing millions of dollars in a generic drug it could not control. For this and other reasons EDTA was left - in terms of its demonstrated utility in various forms of heart disease - in a kind of regulatory limbo.
Worse for the EDTA compound, though, it represented a monumental challenge to the rapidly developing heart disease industry - an essentially due to the low chelation therapy cost, a far less-expensive alternative to complicated, expensive surgical medications.
But research concerning its use went on throughout the world. Dr. Clarke was hailed a chelation pioneer in the Soviet Union, which elevated EDTA chelation therapy to the second most common treatment for artery disease. The chelation therapy cost was much lower, and it became the preferred method of heart disease treatment in Communist-era Czechoslovakia and throughout many countries was administrated successfully against all kinds of blood vessel diseases, gangrene, stroke, senility, diabetes, kidney disorders and other degenerative conditions.
While research went on around the world, with the ultimate publication of literally thousands of articles in scientific and medical journals extolling the multiple benefits of EDTA, the US heart disease industry was growing by leaps and bounds. Regardless of the lower chelation therapy cost over surgery, and just as about the same time, the cancer industry was not about to be sidetracked by laetrile, megavitamins or any other nutritional form of treatment, the heart disease industry looked askance at the use of an old, potentially inexpensive compound cutting into the growing surgical/heart drug business.